Tesamorelin is a synthetic version of GHRH — the same hormone that CJC-1295 mimics — but it's a closer copy of the natural molecule and was developed specifically as a pharmaceutical drug. It was approved by the FDA in 2010 under the name Egrifta, making it one of the few peptides with a complete clinical development program behind it. The approved indication is excess visceral fat in HIV patients, but its mechanism makes it broadly useful for visceral fat reduction.
The way it works is similar to other GHRH analogues: it tells the pituitary gland to release growth hormone, which in turn drives fat breakdown — particularly in visceral fat, the deep abdominal fat that wraps around internal organs. Visceral fat is metabolically active in a harmful way, releasing inflammatory signals and correlating strongly with cardiovascular and metabolic disease. Reducing it has outsized health benefits compared to reducing subcutaneous fat.
In clinical trials, tesamorelin produced significant reductions in visceral adipose tissue — 15–18% on average over 6–12 months — with a favorable safety profile. Unlike taking growth hormone directly, it doesn't cause the insulin resistance or tissue growth that comes with GH supplementation, because it works through the body's own regulated release system.
In the general wellness community, tesamorelin is used for the same reasons it was developed — targeted visceral fat reduction, combined with the broader benefits of increased growth hormone: better sleep, improved body composition, and anti-aging effects. It's commonly stacked with a GHRP like ipamorelin for enhanced GH release.
For educational and research purposes only. Never use any peptide or substance based on information found here — always consult a licensed healthcare professional before making any medical or health-related decision.
Tesamorelin was developed by Theratechnologies and went through a full clinical development program for FDA approval. The Phase 3 trials included over 800 HIV-positive patients with lipodystrophy (abnormal fat redistribution caused by antiretroviral therapy). Results showed consistent 15–18% reductions in visceral adipose tissue measured by CT scan, with improvements in lipid profiles and patient-reported quality of life.
The drug was approved in 2010 and has maintained approval since, which means it has over a decade of post-market safety data in addition to trial data. This level of documentation is unusual for peptides and makes tesamorelin one of the better-understood options in terms of safety.
Unlike CJC-1295, tesamorelin has a shorter half-life and doesn't use a DAC modification — it's cleared within hours, which means it requires daily dosing. This also means its effects on growth hormone follow a more physiological daily rhythm. Some researchers argue this is preferable to the sustained elevation produced by CJC-1295 with DAC.
Off-label use in people without HIV has been studied in smaller trials, showing similar reductions in visceral fat and improvements in IGF-1 levels. The mechanism doesn't depend on having HIV — the visceral fat reduction is a direct metabolic effect of increased GH output.
No reviews yet. Be the first.
AOD9604 is a fragment of human growth hormone — specifically the last 15 amino acids at one end of the molecul…
CJC-1295 is a synthetic version of a hormone your body already produces called GHRH — growth hormone releasing…
IGF-1 LR3 is a modified version of IGF-1 — insulin-like growth factor 1 — a hormone your liver produces in res…